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Abstract: We previously reported how the loss of CHIP expression (Carboxyl terminus of
Hsc70-Interacting Protein) during pressure overload resulted in robust cardiac dysfunction, which
was accompanied by a failure to maintain ATP levels in the face of increased energy demand. In
this study, we analyzed the cardiac metabolome after seven days of pressure overload and found an
increase in long-chain and medium-chain fatty acid metabolites in wild-type hearts. This response
was attenuated in mice that lack expression of CHIP (CHIP−/−). These findings suggest that CHIP
may play an essential role in regulating oxidative metabolism pathways that are regulated, in part, by
the nuclear receptor PPARα (Peroxisome Proliferator-Activated Receptor alpha). Next, we challenged
CHIP−/− mice with the PPARα agonist called fenofibrate. We found that treating CHIP−/− mice
with fenofibrate for five weeks under non-pressure overload conditions resulted in decreased skeletal
muscle mass, compared to wild-type mice, and a marked increase in cardiac fibrosis accompanied
by a decrease in cardiac function. Fenofibrate resulted in decreased mitochondrial cristae density in
CHIP−/− hearts as well as decreased expression of genes involved in the initiation of autophagy and
mitophagy, which suggests that a metabolic challenge, in the absence of CHIP expression, impacts
pathways that contribute to mitochondrial quality control. In conclusion, in the absence of functional
CHIP expression, fenofibrate results in unexpected skeletal muscle and cardiac pathologies. These
findings are particularly relevant to patients harboring loss-of-function mutations in CHIP and are
consistent with a prominent role for CHIP in regulating cardiac metabolism.
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1. Introduction
Carboxyl terminus of Hsc70-interacting protein (CHIP, encoded by the gene STUB1) is a
dual-function enzyme, which has both chaperone-related and ubiquitin ligase activities [1]. Coding
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mutations in STUB1 cause a rare multi-organ disease, and is now identified as SCAR16 (autosomal
recessive spinocerebellar ataxia 16, OMIM: 615768). Clinical phenotypes of SCAR16 patients
include cerebellar ataxia, cognitive dysfunction, and, in some cases, hypogonadism [2,3]. Moreover,
studies suggest that the majority of CHIP coding mutations result in protein destabilization and
loss-of-function [4,5]. The impact of CHIP mutations on cardiac function in SCAR16 patients has not
been reported. However, several laboratories including our own, demonstrated a cardio-protective role
for CHIP in mouse models including cardiac hypertrophy and cardiac ischemia-reperfusion injury [6].
For example, CHIP contributed to cardio-protection by preventing cardiomyocyte apoptosis after
ischemia [7–9]. Additionally, over-expression of CHIP prevented cardiac fibrosis and inflammation
in an angiotensin II-induced model of hypertension [10] and prevented cardiac myogenesis and
pathological hypertrophy under conditions of hyperinsulinemia [11]. In contrast, the genetic deletion
of CHIP was found to enhance both physiological and pathological hypertrophy [12,13]. During
pressure overload, the loss of CHIP also decreased survival, compromised cardiac function, and
reduced metabolic reserves [13]. Metabolic insufficiency in CHIP−/− mice following cardiac pressure
overload occurred in part due to the inability to increase the activation of 5′ AMP-activated protein
kinase (AMPK) [13]. CHIP is required for LKB1-mediated phosphorylation and activation of AMPK
through conformational changes to AMPK in the presence of CHIP that ultimately increase AMPK
activity [13]. AMPK is a master metabolic regulator that senses the cellular energy status through the
binding of adenine nucleotides. Increasing AMPK activity promotes fatty-acid and glucose oxidation.
These data suggest that targeting other metabolic regulators besides AMPK could potentially blunt the
metabolic dysfunction observed in CHIP−/− hearts.
One pharmacological approach to promote cardio-protection in metabolically impaired hearts is
the use of fibrates, which is a class of pharmaceuticals commonly used to lower serum triglycerides
and increase HDL levels in patients with hyperlipidemia [14] as well as for secondary prevention of
cardiovascular disease and stroke [15]. Fibrates are agonists for Peroxisome Proliferator-Activated
Receptor alpha (PPARα), which is a nuclear receptor protein that is activated by endogenous ligands
such as free fatty acids [14]. Upon activation, PPARα induces the hepatic expression of genes involved
in fatty acid oxidation, cellular uptake of fatty acids, synthesis of high-density lipoproteins (HDL),
apoproteins, and lipoprotein lipase while suppressing the expression of apolipoprotein C-III [16–19].
In this paper, we tested the pleiotropic effects of fenofibrate, which has been in use since 1975 and is one
of the most commonly prescribed fibrates [20], on cardiac function in CHIP−/− mice with the initial
goal of using fibrates to possibly compensate for the metabolic deficiencies that occur when the heart
is challenged with a chronic pressure overload. However, in our pharmacological testing of fenofibrate
on cardiac function in non-stressed CHIP−/− mice, we observed unexpected detrimental effects in
skeletal muscle and heart including decreased cardiac function and increased myocardial fibrosis.
Moreover, we found abnormal mitochondria in cardiac sarcomeres in CHIP−/− mice treated with
fenofibrate as well as decreased expression of genes involved in autophagy and mitophagy. Our data
suggest that CHIP expression is necessary for the pleiotropic effects of fenofibrate on cardiac function.
2. Materials and Methods
2.1. Animals
We used CHIP+/− breeding pairs on a 129SvEv background (129S(B6)-Stub1tm1Cpat/Mmnc) to
generate wild-type (CHIP+/+) and CHIP−/− mice. All animal work was performed according to the
Guide for the Care and Use of Laboratory Animals under approved IACUC animal use protocols
within the AAALAC accredited program at The University of North Carolina at Chapel Hill (Animal
Welfare Assurance Number A-3410–01) that comply with NIH standards for care and use.
2.2. Metabolomic Analyses of Hearts
Amino acids, acylcarnitines, and organic acids were measured in snap-frozen, powdered mouse
heart tissue via stable isotope dilution techniques [21–23] (N = 3 hearts per genotype, per condition).
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Samples were equilibrated with a cocktail of internal standards and de-proteinated by precipitation
with methanol. Aliquots of the supernatants were dried and then esterified with hot, acidic methanol
(acyl-carnitines) or n-butanol (amino acids). Data were acquired using a Waters AcquityTM UPLC
system equipped with a TQ (triple quadrupole) detector and a data system controlled by the MassLynx
4.1 operating system (Waters, Milford, MA, USA) [21,22]. We quantified the concentration of organic
acids in samples using the Trace Ultra GC coupled to ISQ MS operating under Xcalibur 2.2 (Thermo
Fisher Scientific, Inc., Waltham, MA, USA) [23].
Metabolite concentrations were analyzed with Metaboanalyst (v3.0) run in the statistical package
R (v3.03) [24,25]. Features with missing data greater than 50% were removed and the remaining
missing values were estimated using KNN (K nearest neighbor). Data were log-transformed and
mean-centered. All metabolites were first evaluated using principal component analysis (PCA). Next,
differences in metabolite concentrations were determined using two-way ANOVA with genotype and
surgery as the main effects. Metabolites were considered differentially present using a false discovery
rate cut off of <10% at either the main effect level or at the interaction level. Raw, processed, and
normalized data along with ANOVA results are available as Supplementary Material. Semi-supervised
hierarchical clustering (Euclidean distance and Ward clustering algorithm) was performed on the
differential variables and visualized using a heatmap.
2.3. Ex Vivo Oxidation and ATP Assays
Oxidation studies utilized fresh heart tissue homogenized in oxidation buffer (75 mM Tris-HCl,
pH 7.4) containing 25 mM sucrose, 30 mM KCl, 5 mM MgCl2, 10 mM KPO4, 1 mM EDTA, 1 mM NAD+,
25 µM cytochrome c, 0.1 mM acetyl-CoA, 0.5 mM malate, 0.5 mM L-carnitine, 5 mM ATP [26,27].
Substrate oxidation was measured using [1-14C]oleate or [U-14C]glucose measured in triplicate per
heart sample (N = 3 per genotype, per condition) using approximately 1 mg to 2 mg of heart protein
per replicate. Reactions were terminated by adding 100 µL of 70% perchloric acid, trapping 14CO2 in
200 µL of 1 N NaOH and counted in Uniscint BD scintillation solution (National Diagnostics, Atlanta,
GA, USA). Acid-soluble metabolites from oleate oxidation were included in total fatty acid oxidation
rates and results are expressed as nanomoles of ATP produced per hour per milligram of protein using
129 and 38 moles of ATP per mole of fatty acid or glucose substrate, respectively [28–30]. Cardiac ATP
concentrations were measured in fresh heart tissue using the ATP Bioluminescence Assay Kit HS II
(Roche, Indianapolis, IN, USA) normalized to protein concentration for each heart sample (N = 6 per
genotype, per condition).
2.4. Fenofibrate Feeding
Mice, 16–18 weeks-of-age, were randomized to receive either standard mouse chow (Prolab RMH
3000, Purina LabDiet, St. Louis, MO, USA) or standard chow formulated with 0.05% w/w fenofibrate
(F6020, Sigma-Aldrich Corp., St. Louis, MO, USA) [31]. Mouse chow (fenofibrate and standard sham
chow) were administered ad libitum starting on day 1 of the protocol and stopped after five weeks.
The number of animals and analyses are listed in Table 1.
Table 1. Design of the experiment.
Genotype No Drug 2 w 5 w
Wild-type (N) 8 5 8
CHIP−/− (N) 6 4 6
Analysis
Echo X X X
Blood labs X X
Histology/RNA X X
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2.5. RNA Isolation and Quantitative Polymerase Chain Reaction (qPCR) Analysis of Gene Expression
Total RNA was isolated from mouse liver or heart (N = 3 animals per genotype, per condition)
using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Germantown, MD, USA) and 500 ng of
RNA was reverse-transcribed into cDNA using iScript Reverse Transcription Supermix (Bio-Rad,
Laboratories, Inc., Hercules, CA, USA). Gene expression assays were performed using either Universal
Probe (UPL) Assays (Roche) or SYBR green chemistry with the indicated oligonucleotides (Table 2) with
FastStart Universal Probe Master Rox (Roche) or FastStart Universal SYBR Green Master Rox (Roche),
respectively, on the 7900HT instrument (Applied Biosystems, Foster City, CA, USA). Efficiencies of
qPCR reactions (1.9–2.1) were confirmed using serial dilution of pooled samples. Three biological
replicates were used in triplicate technical replicates per gene. Relative mRNA levels were calculated
using the delta Cq method. The data was centered using the geometric mean of all control chow
samples and 18S ribosomal RNA levels (4310893E, Applied Biosystems) to normalize loading.
Table 2. Probes and primers used for qPCR analysis.
Gene UPL Probe Sense (5′–3′) Anti-sense (5′–3′)
Acox1 #45 gcgccagtctgaaatcaag actgctgcgtctgaaaatcc
Cpt1a #109 gctgtcaaagataccgtgagc tctccctccttcatcagtgg
Cpt2 #71 ccaaagaagcagcgatgg tagagctcaggcagggtga
Pdk4 #22 ctgcctgaccgcttagtga cttctgggctcttctcatgg
Ucp2 #2 acagccttctgcactcctg ggctgggagacgaaacact
Ppard #11 atgggggaccagaacacac ggaggaattctgggagaggt
Ppargc1a #6 cagtcgcaacatgctcaag tggggtcatttggtgactct
Ppara #41 cacgcatgtgaaggctgtaa cagctccgatcacacttgtc
Acsl1 #84 cagcctcactgcccttttc ggttggtggttctctatgcag
Fabp3 #56 ctttgtcggtacctggaagc tggtcatgctagccacctg
Slc27a #1 gacaagctggatcaggcaag gaggccacagaggctgttc
Slc2a4 #5 gacggacactccatctgttg gccacgatggagacatagc
Atg12 SYBR ggcctcggaacagttgttta cagcaccgaaatgtctctga
Atg4b SYBR attgctgtggggtttttctg aaccccaggattttcagagg
Becn1 SYBR ggccaataagatgggtctga cactgcctccagtgtcttca
Ctsl SYBR gtggactgttctcacgctcaag tccgtccttcgcttcatagg
Gabarapl1 SYBR catcgtggagaaggctccta atacagctggcccatggtag
Lamp2 SYBR tggctaatggctcagctttc atgggcacaaggaagttgtc
Map1lc3b SYBR cgtcctggacaagaccaagt attgctgtcccgaatgtctc
2.6. Measurement of Blood Chemistry
After the animals were euthanized, blood was collected in tubes containing EDTA/citrate. The
blood was then centrifuged at 3000× g for three minutes to separate the plasma from the red blood cells.
Levels of triglyceride, total cholesterol, high-density lipoprotein (HDL) cholesterol, glucose, creatine
kinase, and creatine kinase-MB were measured by the Animal Histopathology and Lab Medicine Core
at The University of North Carolina at Chapel Hill. Low-density lipoprotein (LDL) cholesterol was
calculated using the formula: total cholesterol—HDL—(triglycerides/5).
2.7. Echocardiography
The mice underwent conscious echocardiography using the Vevo 770 ultrasound micro-imaging
system (VisualSonics, Inc., Toronto, ON, Canada) using the model 707B scan head (30 MHz) [32–34].
Two-dimensional guided M-mode echocardiography was performed in the parasternal long-axis view
at the level of the papillary muscle. Wall thickness was then determined by measurements of epicardial
to endocardial leading edges.
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2.8. Morphological Analysis of Tissue by Histology and Transmission Electron Microscopy
For histological assessment, mouse hearts (N = 3 hearts per genotype, per condition) were
perfused with 4% paraformaldehyde, embedded in paraffin, and sectioned into five-micron sections.
Heart sections were stained with either H&E or Masson’s trichrome staining. Whole slides were imaged
using an Aperio Scanscope and analyzed using the Aperio Imagescope software (v10.0.36.1805, Leica
Biosystems, Buffalo Grove, IL, USA). Fibrosis was determined using the Positive Pixel Count Algorithm
to analyze Masson’s trichrome-stained four-chamber sections, with the hue value = 0.66 (blue) and the
hue width = 0.1 (detection threshold above a white background [13,31]. The amount of fibrosis (N = 3
hearts per genotype, per condition) was calculated as the area of fibrotic tissue (blue = collagen) as a
percentage of total tissue area (above background, white). Each heart was represented by multiple
slides including three to four sections per slide. The average fibrosis percentage per heart represents
the mean across slides. The myocyte area was determined similarly using the same heart sections
using NIH ImageJ (v1.38) based on photomicrographs of a standard graticule ruler. Hearts apices
and skeletal muscle were fixed and imaged using a EM910 transmission electron microscope (Zeiss,
Thornwood, NY, USA) [35].
3. Results
3.1. Role of CHIP in Fatty Acid Metabolism
We previously reported surprisingly low cardiac AMPK activity after one week of pressure
overload in CHIP−/− mice despite the increase in metabolic demand [13]. AMPK can drive oxidative
metabolism including fatty acid and glucose oxidation. We measured differences in metabolites from
wild-type and CHIP−/− hearts in the context of pressure overload by trans-aortic banding (TAB)
for one week [13]. Principal components analysis of 74 acylcarnitine, amino acid, and organic acid
metabolites revealed distinct differences in the TAB conditions comparing wild-type and CHIP−/−
hearts (Figure 1a). We identified differential metabolites via two-way ANOVA including an increase
in the carnitine esters of several medium-chain (MC) and long-chain (LC) fatty acids as well as
α-ketoglutarate (Figure 1b). The majority of the differences we observed were manifest in increased
MC and LC acylcarnitines with pressure overload in wild-type hearts, an effect that was attenuated
in CHIP−/− hearts. These data suggest that pressure overload in wild-type hearts results in specific
changes to oxidative metabolic flux that are distinct from those found in CHIP−/− hearts. Using fresh
cardiac homogenates, we measured oxidative metabolism under these same conditions. As expected,
pressure overload resulted in a compensatory increase in ATP production mostly from an increase in
fatty acid oxidation (Figure 1c), which is consistent with the metabolite data (Figure 1b). Remarkably,
in samples from pressure-overloaded CHIP−/− hearts, there was a dramatic drop in glucose oxidation
and, unlike wild-type hearts, there was no increase in fatty acid oxidation, which resulted in an overall
decrease in oxidative ATP generation. We also measured steady-state ATP levels (Figure 1d) and
observed similar patterns to our calculated ATP values (Figure 1e), which highlights the disparity
between wild-type and CHIP−/− hearts after pressure overload. Therefore, we conducted a pilot study
to determine the effect of treating CHIP−/− mice with fenofibrate as a possible approach for rescuing
the metabolic defect seen during pressure overload.
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summarized by the mean ± SEM using either fatty acid (open bars) or glucose (hashed bars) as a 
substrate. Two-way ANOVA for glucose oxidation, N = 3 hearts per genotype per condition: * p < 0.05 
of genotype main effect and interaction between genotype and surgery, post-test: † p < 0.05 glucose 
oxidation in wild-type vs. CHIP−/− after one week of TAB. Two-way ANOVA for fatty acid oxidation, 
* p < 0.05 on surgery main effect. Two-way ANOVA for total ATP, * p < 0.05 on surgery main effect, 
** p < 0.01 on genotype main effect and interaction, post-test: ‡‡ p < 0.01 total ATP in wild-type sham 
vs. TAB mice, post-test, ‡ p < 0.05 total ATP in wild-type vs. CHIP−/− after one week of TAB and the 
surgery-dependent percent change in ATP production rates (TAB vs. sham) in wild-type vs. CHIP−/− 
was significant at p = 0.039. (d) Steady-state ATP levels in mouse hearts represented by dot plot and 
summarized by the mean ± SEM, N = 6 hearts per genotype, per condition. Two-way ANOVA 
interaction of the main effects p = 0.0177, post-test: † p < 0.05 in wild-type vs. CHIP−/− at one week of 
TAB and the surgery-dependent percent change in ATP levels (TAB vs. sham) in wild-type vs. CHIP−/− 
was significant at p = 0.034. (e) Pearson correlation analysis of ATP determined by ex vivo oxidization 
rates (ATPox) or measured steady-state ATP levels (ATPm) * p = 0.0153. 
  
Figure 1. The effects of pressure overload on metabolism in CHIP−/− hearts. Metabolomic analysis of
whole hearts isolated from wild-type or CHIP−/− mice one week after a sham surgery or trans-aortic
banding (TAB) were analyzed using (a) principal component analysis (PCA) and (b) two-way ANOVA,
N = 3 hearts per genotype per condition. Variances captured by the first and third principal components
(PC) are shown. Differential metabolites via ANOVA (FDR < 10%) were clustered and represented by
a heatmap. (c) Ex-vivo oxidative ATP generation rates in mouse heart homogenates summarized by
the mean ± SEM using either fatty acid (open bars) or glucose (hashed bars) as a substrate. Two-way
ANOVA for glucose oxidation, N = 3 hearts per genotype per condition: * p < 0.05 of genotype main
effect and interaction between genotype and surgery, post-test: † p < 0.05 glucose oxidation in wild-type
vs. CHIP−/− after one week of TAB. Two-way ANOVA for fatty acid oxidation, * p < 0.05 on surgery
main effect. Two-way ANOVA for total ATP, * p < 0.05 on surgery main effect, ** p < 0.01 on genotype
main effect and interaction, post-test: ‡‡ p < 0.01 total ATP in wild-type sham vs. TAB mice, post-test,
‡ p < 0.05 total ATP in wild-type vs. CHIP−/− after one week of TAB and the surgery-dependent
percent change in ATP production rates (TAB vs. sham) in wild-type vs. CHIP−/− was significant
at p = 0.039. (d) Steady-state ATP levels in mouse hearts represented by dot plot and summarized
by the mean ± SEM, N = 6 hearts per genotype, per condition. Two-way ANOVA interaction of
the main effects p = 0.0177, post-test: † p < 0.05 i wild-type vs. CHIP−/− at one week of TAB and
the surgery-dependent percent ch nge in ATP levels (TAB vs. sham) in wild-typ vs. CHIP−/− was
significant at p = 0.034. (e) Pearson correlation ana ysis of ATP determined by ex vivo oxidization rates
(ATPox) or measured steady-state ATP levels (ATPm) * p = 0.0153.
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3.2. Fenofibrate-Activated PPARα Target Genes in the Liver
Since the loss of CHIP expression appears to confer a loss of metabolic flexibility, we initiated
a study to challenge CHIP−/− mice with fenofibrate, which is a PPARα agonist, to determine the
effect of a drug known to stimulate oxidative metabolism. Mice were administered fenofibrate by
incorporating the drug into the chow (Table 1). To demonstrate that the fenofibrate dose stimulated
PPARα activity, we first analyzed known hepatic target genes of PPARα in RNA purified from
mouse liver using quantitative PCR (qPCR). As expected, fenofibrate increased expression of Cpt1a
(Carnitine palmitoyltransferase 1a), Cpt2 (Carnitine palmitoyltransferase 2), Ucp2 (Uncoupling protein
2), Acox1 (Acyl-CoA oxidase 1), and Pdk4 (Pyruvate dehydrogenase kinase 4) to similar levels in
both wild-type and CHIP−/− mice (Figure 2a) [36–38]. However, there were no changes in Ppargc1a
(Pparg coactivator 1 alpha), Ppara, and Ppard expression, which suggests no increases in mitochondrial
biogenesis (Figure 2a). Previous reports demonstrated that fenofibrate increased liver weight in
mice [38,39] and, in fact, we observed similar increases in liver weight in both wild-type and CHIP−/−
mice that were fed fenofibrate chow (Figure 2b). Together, these data suggest that the transcriptional
and phenotypic responses to fenofibrate in the liver, which is the primary target organ of fibrates, are
not affected by the loss of CHIP expression.
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Figure 2. The effect of fenofibrate on liver. (a) Quantitative PCR analysis of gene expression in livers
from either wild-type or CHIP−/− mice fed control or fenofibrate chow, which is represented by dot
plot and summarized by the mean ± 95% CI, N = 3 animals per genotype per condition: **, ***, ****
indicate p < 0.01, 0.001, 0.0001 or † p < 0.05 on the main effect of chow or genotype, respectively, via
two-way ANOVA. indicates Tukey’s post-test < 0.05 in comparing fibrate to control conditions within
genotypes. (b) Liver weight normalized to tibia length (TL) is represented by the boxplot w th plotted
biological replicates. Results of tw -way ANOVA are provided, Tukey’s post-test: † and ††† indicate
p < 0.05 and 0.001 comparing control vs. fibrate conditions.
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3.3. Fenofibrate Altered Circulating Cholesterol in Wild-Type But Not CHIP−/− Mice
Fibrates are primarily used to treat hypercholesterolemia and hypertriglyceridemia and, even
though we were not studying models of hyperlipidemia, we investigated the impact of fibrates on
lipid profiles in our model. As expected, there were no changes in triglyceride levels with respect
to genotype or chow (Figure 3a). Paradoxically, we and others observed that fenofibrate increased
the levels of total cholesterol in mice on standard chow (non-Western) diets [31,40]. In this study, we
observed that fenofibrate led to a 58% increase in the total cholesterol levels in WT mice, which is an
effect that was ablated in CHIP−/− mice (Figure 3b). The increase in total cholesterol was comprised
of similar increases in both high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein
cholesterol (LDL-c) in wild-type mice treated with fenofibrate while these levels did not change in
CHIP−/− mice (Figure 3c,d).
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suggests that either skeletal or cardiac muscle may be negatively affected by fenofibrate in the 
absence of CHIP expression. Therefore, we measured various muscle weights and found that the 
tibialis anterior, soleus, and gastrocnemius muscles, on average, were reduced in CHIP−/− mice 
compared to wild-type mice treated with fenofibrate (Figure 4e–g). We did not observe any changes 
Figure 3. Fenofibrate effects on circulating lipid levels. (a) Triglycerides (TG), (b) total cholesterol,
(c) HDL cholesterol, and (d) LDL cholesterol in either wild-type (WT) or CHIP−/− (KO) mice fed
control or fenofibrate chow, which is represented by a boxplot with biological replicates plotted. Results
of two-way ANOVA are provided. Tukey’s post-test: †† indicate p < 0.01 comparing control vs. fibrate
conditions. ## and #### indicate p < 0.01 and 0.0001 comparing WT vs. KO conditions.
3.4. Differential Effects of Fenofibrate on Skeletal Muscle
On average, body weights were lower in CHIP−/− mice compared to wild-type mice (p = 0.0081)
and, after five weeks of fenofibrate, CHIP−/− mice were 23% lighter than wild-type mice (Figure 4a).
CHIP−/− mice trended towards higher fasting blood glucose levels compared to wild-type mice.
However, fenofibrate did not affect fasting blood glucose in either wild-type or CHIP−/− mice
(Figure 4b). Given the known defects in CHIP−/− skeletal muscle [41], we measured creatine kinase
(CK) and creatine kinase-MB (CKMB), which are enzymes that indicate muscle damage. Two-way
ANOVA indicated an interaction between the genotype and the drug treatment with higher CK and
CKMB levels in CHIP−/− mice treated with fenofibrate compared to wild-type mice (Figure 4c,d). This
suggests that either skeletal or cardiac muscle may be negatively affected by fenofibrate in the absence
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of CHIP expression. Therefore, we measured various muscle weights and found that the tibialis
anterior, soleus, and gastrocnemius muscles, on average, were reduced in CHIP−/− mice compared to
wild-type mice treated with fenofibrate (Figure 4e–g). We did not observe any changes in heart weight
(Figure 4h), which suggests that the increase in muscle enzymes seen in CHIP−/− mice treated with
fenofibrate is likely indicative of skeletal muscle atrophy. We previously described accumulation of
lamellar bodies in the gastrocnemius muscle in CHIP−/− mice. Fenofibrate did not appear to affect the
appearance of these structures. However, in both wild-type and CHIP−/− mice on fenofibrate chow,
we observed glycogen accumulation throughout the sarcomere predominantly in the I-band and the
sarcoplasm (Figure 4i,j).
3.5. Fenofibrate Decreased Cardiac Function and Increased Fibrosis in CHIP−/− Mice
We next measured cardiac function at two and five weeks after fenofibrate treatment using
conscious echocardiography (Table 3). There were changes at the two-week time point in CHIP−/−
mice, which included an increase in interventricular septum size in both diastole and systole, as well
as an increase in the calculated left-ventricular (LV) mass, which is suggestive of LV wall thickening.
However, these changes were resolved at the five-week time point. Fenofibrate also caused a modest
11% decrease in cardiac function after five weeks, which was measured by fractional shortening
(Figure 5a). We analyzed ventricle tissue to determine cardiomyocyte surface area and fibrosis using
histochemical approaches developed in our lab (Figure 5b) [13,31]. On average, CHIP−/− mice had
larger cardiomyocytes, but these parameters were not changed with fenofibrate. In contrast, we
observed increased cardiac fibrosis in CHIP−/− mice after fenofibrate treatment (Figure 5d). Although
this increase in fibrosis is modest compared to what we observed in pressure-overloaded hearts
(upwards to 20% fibrosis in CHIP−/− mice [13]), these data suggest that fenofibrate causes some
degree of pathophysiological cardiac remodeling in the absence of CHIP and hemodynamic stress.
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Table 3. Echocardiogram results of study mice. Left ventricular dimension data obtained via conscious echocardiography. When applicable, measurements reported
at diastole or systole (d or s respectively), g, grams, bpm, beats per minute, mm, millimeters, IVS, interventricular septum. LVID, left ventricular internal diameter,
LVPW, left ventricular posterior wall, LV Vol, left ventricle volume; EF, ejection fraction. Results of two-way ANOVA on the main effects (Geno = genotype, Drug = w
of treatment) and the interaction (Inter) are indicated, Tukey’s post-test: *** p < 0.001 comparing 2 w vs. 0 w, #, ##, and ### indicate p < 0.05, 0.01, and 0.001 comparing
wild-type vs. CHIP−/− at 2 w, † and ††† p < 0.05 and 0.001 comparing 5 w vs. 2 w.
Genotype Wild-Type CHIP−/−
Parameter Effect p
Drug 0 2 w 5 w 0 2 w 5 w
N 8 5 8 6 4 6
HR (bpm)
Inter 0.915
600.7 ± 23.8 660.3 ± 17.9 640.5 ± 17.8 602.0 ± 28.0 645.3 ± 26.5 625.5 ± 17.5Geno 0.085
Drug 0.604
IVS;d (mm)
Inter 0.0004
1.07 ± 0.02 0.99 ± 0.02 1.11 ± 0.03 1.04 ± 0.02 1.3 ± 0.5
***,### 1.04 ± 0.06
†††Geno 0.0027
Drug 0.146
LVID;d (mm)
Inter 0.699
3.50 ± 0.16 3.09 ± 0.14 3.35 ± 0.10 3.26 ± 0.14 3.09 ± 0.24 3.3 ± 0.13Geno 0.137
Drug 0.425
LVPW;d (mm)
Inter 0.017
1.04 ± 0.03 1.02 ± 0.01 1.09 ± 0.04 1.00 ± 0.042 1.17 ± 0.07 0.99 ± 0.05 †Geno 0.143
Drug 0.948
IVS;s (mm)
Inter 0.0029
1.75 ± 0.06 1.69 ± 0.05 1.86 ± 0.05 1.74 ± 0.07 2.02 ± 0.06 ## 1.69 ± 0.09 †Geno 0.247
Drug 0.398
LVID;s (mm)
Inter 0.263
1.61 ± 0.08 1.39 ± 0.09 1.43 ± 0.05 1.49 ± 0.09 1.51 ± 0.20 1.63 ± 1.11Geno 0.572
Drug 0.426
LVPW;s (mm)
Inter 0.473
1.59 ± 0.04 1.57 ± 0.08 1.68 ± 0.07 1.53 ± 0.05 1.53 ± 0.06 1.5 ± 0.05Geno 0.782
Drug 0.068
LV Vol;d (µL)
Inter 0.617
51.92 ± 5.57 38.30 ± 4.02 46.04 ± 3.07 43.46 ± 4.40 38.84 ± 7.82 44.86 ± 4.39Geno 0.161
Drug 0.447
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Table 3. Cont.
Genotype Wild-Type CHIP−/−
Parameter Effect p
Drug 0 2 w 5 w 0 2 w 5 w
N 8 5 8 6 4 6
LV Vol;s (µL)
Inter 0.254
7.46 ± 0.91 5.13 ± 0.88 5.51 ± 0.51 6.16 ± 1.03 6.80 ± 2.42 7.89 ± 1.20Geno 0.723
Drug 0.329
LV Mass (mg)
Inter 0.0039
140.18 ± 7.13 109.95 ± 6.87 140.74 ± 8.32 120.86 ± 11.18 150.08 ± 8.21 # 122.31 ± 11.08Geno 0.986
Drug 0.917
EF (%)
Inter 0.087
85.42 ± 0.75 86.89 ± 1.0 87.78 ± 1.12 86.05 ± 0.86 83.84 ± 2.40 82.7 ± 1.71Geno 0.915
Drug 0.021
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Figure 5. Changes in cardiac function and structure due to fenofibrate. (a) Fractional (fract.) shortening
over the time course of the study, which is represented by boxplot with biological replicates plotted.
Results of two-way ANOVA are provided. Tukey’s post-test: # p < 0.05 comparing wild-type (WT) vs.
CHIP−/− (KO) conditions. (b) Micrographs of Masson’s trichrome staining of heart sections in which
the scale bar represents 100 microns. (c) Cardiomyocyte area and (d) the percentage of fibrotic cardiac
tissue represented by dot plot and summarized by the mean ± 95% CI, N = 3 animals per genotype per
condition. The results of two-way ANOVA are provided. Tukey’s post-test: # and ## p < 0.05 and 0.01
comparing WT vs. KO conditions; †† p < 0.01 control vs. fibrate conditions.
3.6. The Effect of Fenofibrate on Mitochondrial Ultrastructure in the Cardiac Sarcomere and on the Expression
of Metabolic, Autophagy, and Mitophagy Genes
e reviously did not observe any structural differences in the sarcomeres of unstressed CHIP−/
earts [13]. o ever, in hearts from CHIP− mice treated with fenofibrate, e foun vario s regio s
it ex a e sarco las ic retic l as ell as c a ges i itoc o rial or ology i cl i g
ecrease cristae ensity (Fig re 6a) in co arison ith il -ty e sarco eres (Fig re 6b). ecycling
of protein aggregates and mitochondria occur through the related autophagy and mitophagy pathways.
These pathways in the heart are activated by several cardio-protective compounds [42] including
fenofibrate [43–45]. Moreover, CHIP is known to play an important role in autophagy [12,46–50]. To
explore the mechanism behind the phenotype observed in CHIP−/− mice, we used qPCR analysis to
determine if fenofibrate had differential effects on metabolic or autophagy/mitophagy gene expression
in hearts isolated from CHIP−/− versus wild-type mice.
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We identified similar patterns of metabolic gene expression in fenofibrate-treated mice, 
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Figure 6. The effect of fenofibrate on mitochondrial ultrastructure and gene expression in the absence
of CHIP. Transmission electron micrographs of left ventricle tissue from (a) CHIP−/− and (b) wild-type
mice. Expanded sarcoplasm regions are observed throughout CHIP−/− hearts (outlined in boxes).
Alterations in mitochondria were also observed in CHIP−/− hearts (X) and compared to wild-type
hearts (O). Quantitative PCR analysis of gene expression of (c) metabolic or (d) autophagy/mitophagy
mRNA in hearts from either wild-type or CHIP−/− mice fed control or fenofibrate chow,represented
by dot plot and summarized by the mean ± 95% CI, N = 3 animals per genotype per condition: **, ***,
**** indicate p < 0.01, 0.001, 0.0001 on the main effect of chow, †, ††, ††† indicate p < 0.05, 0.01, 0.001 on
the main effect of genotype, or ‡, ‡‡ indicate p < 0.05, 0.01 the interaction of chow and genotype via
t o-way ANOVA. ¶ indicates the Tukey’s post-test < 0.05 in co paring fibrate to control conditions
within genotypes.
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We identified similar patterns of metabolic gene expression in fenofibrate-treated mice,
irrespective of CHIP expression (Figure 6c) suggesting that other cellular pathways may be implicated
in the phenotypes we observed. In contrast, a different pattern appeared in the analysis of
autophagy/mitophagy-related genes (Figure 6d). In wild-type mice, fenofibrate increased the
expression of Lamp2 and Ctsl, which are genes that encode enzymes involved in lysosomal function
and the formation of the autolysosome [51], and Gabarapl1, which is a gene that encodes a
phospholipid-interacting protein involved in the later stages of autophagosome maturation [52].
In CHIP−/− mice, we also measured a similar increase in Lamp2 expression (Figure 6d). However,
several genes involved in the initiation of autophagosome formation including Becn1, Atg12, Atg4b,
and Map1lc3b [51] were decreased in CHIP−/− mice when treated with fenofibrate (Figure 6d). These
data are consistent with the role of CHIP in regulating autophagy-related pathways [12,46–50] and the
disruption of regulation is more pronounced in conditions that may activate autophagy/mitophagy
such as therapies that include fibrates.
4. Discussion
Pressure overload and the subsequent pathological remodeling in the heart is associated with
changes in cardiac metabolism [53–55]. In the initial compensatory phase of pressure overload, the
heart adapts to the increased demand and can maintain cardiac output. However, over time, if the
stress is not relieved, this adaptation turns to maladaptation and eventual heart failure. In our mouse
model of pressure overload, the initial adaptation is exemplified after one week, since wild-type
hearts maintain function in part due to compensatory cardiomyocyte hypertrophy [13]. Deletion
of CHIP in mice results in the inability to meet cardiac energy demands during pressure overload,
which leads to robust cardiac hypertrophy and impaired cardiac function [13]. This may be reflective
of the metabolic inflexibility of CHIP−/− mice to pathological stressors. We used metabolomics
(Figure 1a) to identify changes that occur during this adaptive phase in both wild-type and CHIP−/−
mice. We observed an increase in long-chain and medium-chain acylcarnitines (Figure 1b) that
was accompanied by an increase in fatty acid oxidation and total oxidation (Figure 1c) as well as
increased ATP levels (Figure 1d,e), which is consistent with our previous report [13]. These effects
were attenuated in CHIP−/− mice (Figure 1b–e), which is consistent with our hypothesis that CHIP
is necessary for cardiac metabolic flexibility. We decided to test the effect of stimulating oxidative
metabolism pharmacologically using the PPARα agonist, fenofibrate, in CHIP−/− mice. Unexpectedly,
treating CHIP−/− animals with fenofibrate decreased cardiac function (Figure 5a) accompanied with
increased cardiac fibrosis (Figure 5b,d). Changes in mitochondrial ultrastructure were observed in
CHIP−/− mice treated with fenofibrate including a decrease in cristae density (Figure 6a). Fenofibrate
can induce changes in hepatic mitochondria in rodents, canines, and humans [56,57]. Mitochondrial
impairment is thought to mediate the toxicity of fibrates as well as statins and thiazolidinediones [58].
Therefore, the cardiac effects seen in CHIP−/− mice treated with fenofibrate may be a result of impaired
mitochondrial function or quality control via mitophagy (Figure 6d).
PPARα target genes in the heart are poorly defined. As such, fenofibrate did not result in increased
transcription of several genes involved in fatty acid oxidation in mouse hearts from either genotype
(Figure 6c). However, we found that the expression of hepatic genes known to be responsive to
PPARα agonists were regulated to a similar extent in wild-type and CHIP−/− animals (Figure 2a).
This suggests that CHIP expression was not necessary for hepatic PPARα-mediated gene transcription.
Likewise, we saw an equivalent increase in liver mass with fenofibrate in mice of either genotype
(Figure 2b), which was shown previously in multiple mouse lines [37,38,59]. In contrast, fenofibrate
had differential effects on circulating lipids when comparing wild-type and CHIP−/− animals. As
seen in other mouse models [31,40], fenofibrate increased total, HDL-cholesterol, and LDL-cholesterol
levels in wild-type mice, which is a response that was entirely absent in CHIP−/− mice (Figure 3b–d).
We also found that fenofibrate had deleterious effects on skeletal muscle in CHIP−/− mice. These
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effects include an increase in muscle proteins in the circulation (Figure 4c,d) and a decrease in muscle
mass (Figure 4e–g).
Published findings present a mixed picture regarding the effects of fenofibrate on cardiac
function in animal models. The majority of studies demonstrate a protective role of fenofibrate
on cardiac function by decreasing the degree of cardiac remodeling and fibrosis, which was seen
in mouse, rat, and canine models [43,60–64]. In contrast, in mouse models with altered cardiac
metabolism, fenofibrate appears to mediate pathophysiological responses. For example, fenofibrate
promoted cardiac hypertrophy in mice lacking MuRF1 expression. However, there were no changes
in fibrosis, ejection fraction, of fractional shortening [31]. Likewise, fenofibrate treatment increased
cardiac hypertrophy and fibrosis along with a decrease in fractional shortening during pressure
overload in PPARα deficient mice [65]. These later studies, combined with our results, highlight
deleterious consequences of fibrate treatment in the context of altered cardiac metabolism. Clinically,
there are reported incidences of fenofibrate-related side effects including liver fibrosis [66] and
nephrotoxicity [67]. Moreover, these findings may be particularly relevant in patients with MuRF1 or
with CHIP loss-of-function mutations [2,3,68,69]
Future studies will focus on understanding the metabolic changes accompanying fenofibrate
treatment of CHIP−/− mice and whether they differ from those in wild-type animals including
deleterious effects on cardiac mitochondria. Additionally, defining the integrated stimuli that induces
pathological remodeling in CHIP−/− hearts will help to elucidate the sensitization caused by the loss
of CHIP function.
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